Exosomes and anti-tumour immunotherapy;Exosomes et immunothérapie antitumorale

Bulletin du Cancer

Volumn 90, Issue 8-9, 2003, Pages 695-698

  Chaput, Nathalie ^a   Andre, Fabrice ^a   Schartz, Noël E C ^a,b   Flament, Caroline ^a   Angevin, Eric ^a   Escudier, Bernard ^a   Zitvogel, Laurence ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Exosome; Immunotherapy; Tumor

Indexed keywords

AMPLIGEN; CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG;

CANCER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; DENDRITIC CELL; ENDOSOME; EPITHELIUM CELL; EXOSOME; HEMATOPOIETIC CELL; HUMAN; IMMUNOGENETICS; MEMBRANE VESICLE; MOLECULAR BIOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; T LYMPHOCYTE; TUMOR CELL;

ANIMALS; ANTIGEN-PRESENTING CELLS; CARCINOMA, NON-SMALL-CELL LUNG; CYTOPLASMIC VESICLES; FEASIBILITY STUDIES; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MELANOMA; MICE; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0141887651     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Denzer K, et al. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000; 113: 3365-74.
2. Denzet K, et al. Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. J Immunol 2000; 165: 1259-65.
3. Quah B, O'Neill HC. The application of dendritic cell-derived exosomes in tumour immunotherapy. Cancer Biother Radiopharm 2000; 15: 185-94.
4. André F, et al. Malignant effusions and immunogenic tumor derived-exosomes. Lancet 2002; 360: 295-305.
5. Zitvogel L, et al. Eradication of-established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nature Med 1998; 4: 594-600.
6. Wolfers J, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nature Med 2001; 7: 297-303.
7. Johnstone RM, et al. Vesicle formation during reticulocyte maturation: association of plasma membrane activities with released vesicles (exosomes). J Biol Chem 1987; 262: 9412-20.
8. Raposo G, et al. Accumulation of major histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation. Mol Biol Cell 1997; 8: 2631-45.
9. Escola JM, et al. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem 1998; 273: 20121-7.
10. Arnold PY, Mannie MD. Vesicles bearing MHC class II molecules mediate transfer of antigen-presenting cells to CD4 + cells. Eur J Immunol 1999; 29: 1363-73.
11. Heijnen IA, et al. Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest 1996; 97: 331-8.
12. Hess C, et al. Ectosomes released by human neutrophils are specialized functional units. J Immunol 1999; 163: 4564-73.
13. Parel D, et al. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition. J Immunol 1999; 163: 5201-10.
14. Geminard C, et al. Characteristics of the Interaction between Hsc70 and the transferrin receptor in exosomes released during reticulocyte maturation. J Biol Chem 2001; 276: 9910-16.
15. Skokos D, et al. Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J Immunol 2001; 166: 868-76.
16. Thery C, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999; 147: 599-610.
17. Thery C, et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 2001; 166: 7309-18.
18. Clayton A, et al. Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Methods 2001; 247: 163-74.
19. Raposo G, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996; 183: 1161-72.
20. van Niel G, et al. Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology 2001; 121: 337-49.
21. Pan BT, et al. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol 1985; 101: 942-8.
22. Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nature Rev Immunol 2002; 2: 569-79.
23. Blanchard N, et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/z complex. J Immunol 2002; 168: 3235-42.
24. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999; 94: 3791-9.
25. Hanayama R, et al. Identification of a factor that links apoptotic cells to phagocytes. Nature 2002; 417: 182-7.
26. Lamparski H, et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 2002; 270: 211.
27. Théry C, Duban L, Segura E, Véron P, Lantz O, Amigorena S. Exosomes activate naive CD4 + T cells by transfer of MHC/peptide complexes to dendritic cells. Nature Immunol 2002; 3: 1156-62.
28. Vincent-Schneider H, Stumptner-Cuvelette P, Lanka D, Pain S, Raposo G, Benaroch P, Bonnerot C. Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int Immunol 2002; 14: 713-22.
29. Escudier B, Dorval T, Angevin E, Boccaccio C, Robert C, Avril MF, et al. Novel approach to immunotherapy of cancer: phase I trial of dexosome vaccine for patients with advanced melanoma. Proc Am Soc Clin Oncol 2002; A1857.